
| 4 min read
Psychedelic acquisitions, clinical trial updates, and more led the news this week.
| 5 min read
Aurion Biotech's manufacturing approach to unmodified allogeneic corneal endothelial cells offers a set of hard-won lessons for a cell therapy field still working out how to get from proof-of-concept to broad patient access.
| 3 min read
A new platform combines engineered viral vectors with the brain's glymphatic system to improve gene delivery to glial cells implicated in multiple neurological disorders.
| 3 min read
KCL-286 repaired neuronal DNA damage and reduced neuroinflammation in mice, with prior Phase 1 safety data potentially accelerating its path to Alzheimer's trials.News
Cancer Research News
Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence.
New population-level data reveal unprecedented declines in cervical cancer among vaccinated cohorts, even as vaccination rates begin to slip in some countries.
Editor's Pick
Born to differentiate and heal, mesenchymal stem cells carry great potential for treating a wide spectrum of diseases.
In a journey fraught with heartache and persistence, medical research giants paved the way for successful bone marrow transplantation.
Multimedia
Philip Wills, Chief Commercial Officer of the Cell & Gene Therapy Division at Catalent, reflects on how the gene therapy industry is evolving from early scientific breakthroughs to commercial maturity.
Learn the key characteristics that determine whether an immunoassay generates accurate and reproducible data.





















